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The majority of chronic liver diseases are accompanied by oxidative stress,
which induces apoptosis in hepatocytes and liver injury. Recent studies suggest
that oxidative stress and insulin resistance are important in the pathogenesis of
nonalcoholic fatty liver disease (NAFLD) and the pathophysiology of diabetes
complications. Metformin has been shown to be hepatoprotective in the insu-
lin-resistant and leptin-deficient ob/ob mouse model of NAFLD. However, the
mechanism involved in the protective effects of metformin has not been eluci-
dated yet. Therefore, we investigated the protective effect of metformin against
oxidative stress-induced apoptosis. Primary rat hepatocytes were exposed to the
oxidative stress-generating compound menadione in the presence and absence
of metformin. Apoptosis was determined by measuring caspase activity and
poly(ADP-ribose) polymerase (PARP)-cleavage, and necrosis was measured by
Sytox Green nuclear staining. We demonstrate that (1) Metformin inhibits
menadione-induced caspase-9,-6,-3 activation and PARP-cleavage in a concen-
tration-dependent manner. (2) Metformin increases menadione-induced heme
oxygenase-1 (HO-1) expression and inhibits c-Jun N-terminal kinase (JNK)-
phosphorylation. (3) Metformin does not induce necrosis in primary hepato-
cytes. Metformin protects hepatocytes against oxidative stress-induced caspase
activation, PARP-cleavage and apoptosis. The anti-apoptotic effect of metfor-
min is in part dependent on HO-1 and bcl-xl induction and inhibition of JNK
activation and independent of insulin signaling. Our results elucidate novel pro-
tective mechanisms of metformin and indicate that metformin could be investi-
gated as a novel therapeutic agent for the treatment of oxidative stress-related
liver diseases.
Abbreviations
H2S, hydrogen sulfide; SDS-PAGE, sodiumdodecyl sulphate polyacrylamide gel elec-
trophoresis; ROS, reactive oxygen species; O2
•, superoxide anions; H2O2, hydrogen
peroxide; HO-1, heme oxygenase-1; PARP, poly(ADP-ribose) polymerase; MAPK,
mitogen-activated protein kinase; JNK, c-Jun N-terminal kinase; GAPDH, glyceral-
dehyde 3-phosphate dehydrogenase; IRS-1, insulin receptor substrate-1; NAFLD,
nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis.
Introduction
Most chronic liver diseases are accompanied by oxidative
stress (Bomzon et al. 1997; Reid 2001; Loguercio and Fede-
rico 2003), which may induce cell death (apoptosis and/or
necrosis) in hepatocytes, leading to liver injury. Apoptosis,
or programmed cell death (Nieminen 2003; Nikoletopou-
lou et al. 2013; Stevens et .al. 2013), is an active process
characterized by cell shrinkage, chromatin condensation,
and activation of caspases (Riedl and Shi 2004; Shi 2002),
and formation of apoptotic bodies. In contrast, necrosis is
associated with ATP depletion, rupture of the plasma mem-
brane, and spilling of the cellular content eliciting inflam-
mation (Nieminen 2003; Nikoletopoulou et al. 2013;
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Stevens et al. 2013). Although necrosis has traditionally
been considered passive cell death as opposed to apoptotic
or programmed cell death, there is increasing evidence that
necrotic cell death is also dependent on active intracellular
signaling pathways and that some of these signaling path-
ways are shared with apoptotic cell death, for example, the
mitochondrial permeability transition (Samali et al. 1999;
Nieminen 2003; Yuan and Kaplowitz 2009; Jaeschke et al.
2012; Nikoletopoulou et al. 2013; Stevens et al. 2013). To
underscore the fact that necrosis and apoptosis are actually
two sides of the same coin, the term necroapoptosis has
been adopted and it has been described that cells can switch
between these modes of cell death, depending on specific
conditions, for example, intracellular ATP levels and redox
status (Samali et al. 1999; Nieminen 2003; Yuan and Ka-
plowitz 2009; Jaeschke et al. 2012; Nikoletopoulou et al.
2013; Stevens et al. 2013). Recent studies suggest that oxi-
dative stress and insulin resistance are important in the
pathogenesis of nonalcoholic fatty liver disease (NAFLD)
and the pathogenesis of complications of diabetes (Maech-
ler and Wollheim 2001; Rosen et al. 2001; Du et al. 2003;
Evans et al. 2003; Wiernsperger 2003; Marchetti et al. 2004;
Bugianesi et al. 2005; Machado and Cortez-Pinto 2005).
Metformin, an antihyperglycemic agent used in type 2
diabetes, has been shown to have beneficial effects in
many studies (Mataforme et al. 2011; Barbero-Becerra
et al. 2012; Cicero et al. 2012; Mazza et al. 2012). In
addition, metformin has been shown to be hepatoprotec-
tive in the insulin-resistant and leptin-deficient ob/ob
mouse model of NAFLD (Lin et al. 2000). Metformin
also appears to have beneficial effects on (liver) diseases
not directly related to insulin resistance, including tumor-
igenesis (Cicero et al. 2012; Kita et al. 2012; Quinn et al.
2013). In nondiabetic experimental animal models, met-
formin prevents endotoxin-induced liver injury after par-
tial hepatectomy (Bergheim et al. 2006) and protects
against carbon tetrachloride-induced hepatotoxicity in
mice (Poon et al. 2003). Furthermore, metformin has
been shown to protect endothelial cells and neuronal cells
in several in vitro toxicity models, possibly related to pro-
tection against oxidative stress (El-Mir et al. 2008; Eriks-
son et al. 2012; Bhatt et al. 2013). However, the
mechanism(s) involved in these protective effects of met-
formin has not been elucidated yet.
Since metformin may have protective effects, in partic-
ular against oxidative stress, that are not related to
improving insulin-resistance, we investigated whether
metformin has any protective effect against oxidative
stress-induced apoptosis in primary rat hepatocytes. We
demonstrate that metformin protects primary rat hepato-
cytes against oxidative stress-induced apoptosis. The pro-
tective effect of metformin is in part dependent on the
induction of heme oxygenase-1 (HO-1) and bcl-xl and
inhibition of c-Jun N-terminal kinase (JNK) activation,
and is independent of insulin signaling.
Hence, metformin could represent an important thera-




Specified pathogen-free male Wistar rats (220–250 g) were
purchased from Harlan (Zeist, the Netherlands). They were
housed under standard laboratory conditions with free
access to standard laboratory chow and water. Experiments
were performed following the guidelines of the local Com-
mittee for Care and Use of laboratory animals.
Rat hepatocyte isolation
Rat hepatocytes were isolated as described previously
(Moshage et al. 1990) and cultured in William’s E medium
(Invitrogen, Breda, the Netherlands) supplemented with
50 lg/mL gentamicin (Invitrogen) without the addition of
insulin or growth factors. During the attachment period
(4 h), 50 nmol/L dexamethasone (Sigma, St. Louis, MO,
USA), and 5% fetal calf serum (Invitrogen) were added to
the medium. After the attachment period of 4 h, cells were
washed and cultured in serum-free medium without insu-
lin or dexamethasone. Cells were cultured in a humidified
incubator at 37°C and 5% CO2. Hepatocyte viability was
always more than 90% and purity more than 95% as deter-
mined by Trypan blue exclusion assay. All the experiments
were performed in the absence of insulin.
Experimental design
Experiments were started 24 h after isolation of hepato-
cytes (20 h after attachment). At this time point, it was
assumed that no effects of insulin or dexamethasone are
present. As a model of oxidative stress-induced apoptosis,
we used menadione (2-methyl-1,4-naphthoquinone). The
quinone menadione undergoes one- electron reduction
catalyzed by NADPH-cytochrome P-450 reductase or
NADH ubiquinone oxidoreductase, yielding a semiqui-
none reactive intermediate that undergoes redox cycling
to generate superoxide anions (O2
•) (Thor et al. 1982).
This model has been described before and induces pre-
dominantly apoptotic cell death in primary cultures of rat
hepatocytes (Conde de la Rosa et al. 2006). Cells were
exposed to menadione (50 lmol/L; Sigma) for the indi-
cated time and/or metformin (0.1–0.5 mmol/L), added
10 min before menadione treatment. The concentrations of
metformin used were based on our previous study in
2015 | Vol. 3 | Iss. 2 | e00125
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which the protective effect of metformin on bile acid-
induced apoptosis was described and represent the two
lowest effective concentrations of metformin against mena-
dione-induced apoptosis (Woudenberg-Vrenken et al.
2013). In some experiments, the insulin-sensitizing drug
rosiglitazone (0.5–10 lmol/L) and insulin (50 nmol/L)
was used.
Caspase enzyme activity assays
Caspase-3 enzyme activity was assayed as described previ-
ously (Schoemaker et al. 2004). Caspase-6 activity was
assayed according to the manufacturer’s instructions (Bio-
Vision, Milpitas, CA, USA).
Sytox green nuclear staining
Rupture of the plasma membrane distinguishes necrotic
from apoptotic cell death. To estimate necrotic cell death,
hepatocytes were incubated 15 min with Sytox green
(Molecular Probes, Eugene, OR) nucleic acid stain, which
penetrates cells with compromised plasma membranes
but does not cross the membranes of viable cells or apop-
totic bodies. Fluorescent nuclei were visualized using an
Olympus CKX41 microscope at 450–490 nm. Hepatocytes
exposed to 5 mmol/L hydrogen peroxide (H2O2) were
used as a positive control for necrosis (Conde de la Rosa
et al. 2006).
Western blot analysis
Western blot analysis of cell lysates was performed by SDS-
PAGE (sodiumdodecyl sulphate polyacrylamide gel electro-
phoresis) followed by transfer to Hybond ECL nitrocellu-
lose membrane (Amersham - GE Electric, Eindhoven, The
Netherlands). An antibody against glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) (Calbiochem, San Diego,
CA, USA) and Ponceau S staining were used to ensure
equal protein loading and electrophoretic transfer.
Caspase cleavage was detected using polyclonal rabbit
antibodies against cleaved caspase-9, -6, and -3. Poly(ADP-
ribose) polymerase (PARP) cleavage was detected with a
rabbit anti-PARP polyclonal antibody (Cell Signaling, Bev-
erly, MA). PARP (116 kDa) is a substrate of caspase-3
yielding a product of 89 kDa and it is considered a late
marker for apoptosis. Phosphorylation of IRS-1 (insulin
receptor substrate-1) was determined using an antibody
against Ser612-phosphorylated IRS-1. After western blot
analysis for p-JNK (monoclonal; Santa Cruz Biotechnol-
ogy, Dallas, TX, USA), blots were stripped using 0.1% SDS
in PBS/Tween-20 at 65°C for 30 min and incubated with
antibodies against total-JNK. Antibodies against p-JNK
and phosphorylated IRS-1 were obtained from Cell Signal-
ing Technology and used at 1:1000 dilution. Western blot
for phosphorylated IRS-1 was quantified by densitometry
using the Biorad PhotoDoc system and software (Image
Lab vs. 3.0: Belgrade, MT, USA).
RNA isolation and quantitative real-time
PCR
RNA was isolated using the Tri-reagent (Sigma) according
to the manufacturer’s instructions Reverse transcription
was performed on 2.5 lg of total RNA using random
primers in a final volume of 50 lL (reverse transcription
system; Sigma). Real-time detection was performed on
the ABI PRISM 7700 (PE Applied Biosystems - Thermo
Fisher Scientific, Breda, The Netherlands) initialized by
10 min at 95°C, followed by 40 cycles of 15 sec at 95°C,
and 1 min at 60°C. Each sample was analyzed in dupli-
cate. 18S mRNA levels were used as an endogenous con-
trol. Real-time PCR primers and probes for HO-1
(Conde de la Rosa et al. 2008): Forward: CAC AGG GTG
ACA GAA GAG GCT AA; Reverse: CTG GTC TTT GTG
TTC CTC TGT CAG; Probe: CAG CTC CTC AAA CAG
CTC AAT GTT GAG C and for Bcl-xl: Forward: TTG
TGG ATC TCT ACG GGA ACA AT; Reverse: GTC AGG
AAC CAG CGG TTG AA; Probe: CTC CTG GCC TTT
CCG GCT CTC G.
Statistical analysis
All data are expressed as the mean of 3–5 independent
experiments  SD. Statistical significance was determined
by the Mann–Whitney test; P < 0.05 was considered sta-
tistically significant.
Results
Metformin but not rosiglitazone protects
against menadione-induced caspase
activation, PARP cleavage, and apoptosis
We investigated whether metformin exerts a protective
effect against oxidative stress-induced apoptosis. As
shown in Figure 1A, metformin inhibits oxidative stress-
induced apoptosis (expressed as caspase-3 activity) in pri-
mary hepatocytes. The protective effect of metformin
reached its maximum at 0.5 mmol/L. In addition, metfor-
min inhibits menadione-induced PARP-cleavage, which is
considered a late marker for apoptosis (Fig. 1B), suggest-
ing a protective role of metformin against oxidative
stress-induced apoptosis.
In previous studies, we showed that menadione at the
concentration used, induces predominantly caspase-
dependent apoptotic cell death but hardly any necrotic
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cell death in primary rat hepatocytes (Conde de la Rosa
et al. 2006, 2008). In these studies, we also demonstrated
activation of caspases-3, 6, and 9 in menadione-induced
apoptosis in rat hepatocytes. Therefore, we analyzed
whether metformin has an effect on the activation of
these caspases. Metformin prevents menadione-induced
capase-6 activity (Fig. 2A) and caspase-9, -6, and -3 cleav-
age in primary rat hepatocytes (Fig. 2B).
In addition, metformin did not induce significant
necrosis in primary hepatocytes (Fig. 3), indicating that
metformin is protective against oxidative stress-induced
apoptosis and does not switch the balance between apop-
tosis and necrosis. Since metformin has been reported to
partially reverse the insulin-resistance in diabetes mellitus
type 2, we also investigated the effect of the insulin-sensi-
tizing drug rosiglitazone on oxidative stress-induced
apoptosis. Rosiglitazone up to 10 lmol/L did not protect
against oxidative stress-induced apoptosis, but rather
increased oxidative stress-induced apoptotic hepatocyte
death (Fig. 4A). Moreover, insulin at 50 nmol/L did not
inhibit menadione-induced hepatocyte apoptosis (data
not shown). Finally, we investigated whether metformin
and/or menadione have any effect on insulin-signaling,
using IRS-1 as a downstream target of insulin. As shown
in Figure 4B, insulin-induced phosphorylation of IRS-1.



















Con Men 50 μmol/L Men + 
Met 0.1 mmol/L
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Figure 1. Metformin prevents oxidative stress-induced apoptosis and PARP cleavage in a concentration-dependent manner. Primary hepatocytes
were exposed to metformin (Met, 0.1 mmol/L and 0.5 mmol/L) 10 min before and during menadione (Men, 50 lmol/L, 9 h) treatment. Control
(con, untreated cells). (A) Caspase-3 activity assay. (B) Western blot was performed against native (116 kDa) and cleaved (89 kDa) PARP. GAPDH
was used as a loading control. Statistical analysis: *P < 0.05 compared to control. #P < 0.05 compared to menadione-treated cells; n = 5. PARP,
poly(ADP-ribose) polymerase.
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lated by menadione. Metformin alone or in the presence
of insulin slightly but significantly increased phosphoryla-
tion of IRS-1.
Metformin reduces oxidative stress-induced
JNK phosphorylation
We have previously demonstrated that oxidative stress-
induced hepatocyte death is dependent on JNK activation,
since menadione activates JNK and inhibition of JNK
activity abolished oxidative stress-induced apoptosis
(Conde de la Rosa et al. 2004; 2008) Therefore, we exam-
ined the effect of metformin on menadione-induced JNK
activation.
In the current study, metformin does not induce JNK-
phosphorylation, but reduces menadione-induced
JNK-phosphorylation (Fig. 5). The residual JNK-phos-
phorylation observed in control hepatocytes is most
likely the result of a basal phosphorylation due to isola-
tion and culture manipulations. Interestingly, the inhibi-
tory effect of metformin appeared to be stronger on the
JNK p54 isoforms than the p46 isoforms. This is similar
to the effect of the HO-1 product carbon monoxide on
JNK-phosphorylation, as reported previously (Conde de
la Rosa et al. 2008). These results suggest that the protec-
tive effect of metformin against oxidative stress-induced
apoptosis is in part via inhibition of JNK (p54) activa-
tion.
Metformin induces menadione-induced HO-1
expression
HO-1 has been described to be cytoprotective against oxi-
dative stress. Previously, we showed that the superoxide
anion donor menadione induces HO-1 expression in a
time and concentration-dependent manner, although not
sufficiently to prevent apoptosis. However, we demon-
strated that overexpression of HO-1, using the adenovirus
Ad5HO-1, leads to protection against oxidative stress-
induced apoptosis in primary hepatocytes (Conde de la
Rosa et al. 2008). This prompted us to investigate
whether metformin has any effect on HO-1 expression.
As shown in Figure 6, metformin further increases mena-
dione-induced HO-1 expression, although metformin




HO-1 induction has been demonstrated to correlate with
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Figure 2. Metformin blocks menadione-induced caspase-9, -6 and -3 activation in a dose-dependent manner in primary rat hepatocytes. Cells
were incubated with the superoxide anion–donor menadione (Men, 50 lmol/L, 9 h) or not (control, untreated cells) in the presence and absence
of metformin (Met, 0.1 mmol/L and 0.5 mmol/L, added 10 min before and during menadione treatment). (A) Caspase-6 activity assay: Metformin
dose-dependently prevents caspase-6 activation. (B) Western Blot: Metformin inhibits caspase-9, -6, and -3 processing and cleavage induced by
the superoxide anion-donor menadione in a concentration-dependent manner. GAPDH was using as a loading control. Statistical analysis:
*P < 0.05 compared to control. #P < 0.05 compared to menadione-treated cells; n = 5. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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member bcl-xl (Goodman et al. 2007; Banerjee et al.
2012). Since we have previously shown that bcl-xl is
expressed in hepatocytes (Schoemaker et al. 2002), we
investigated the effect of oxidative stress and metformin
on bcl-xl expression. As shown in Figure 7, metformin
further promoted menadione-induced bcl-xl expression.
Notably, metformin alone dose dependently increases bcl-
xl expression in primary rat hepatocytes.
Discussion
Many studies have shown that metformin has beneficial
effects in the treatment of type 2 diabetes (Inzucchi et al.
1998; Knowler et al. 2002; Mataforme et al. 2011; Cicero
et al. 2012), a disorder that has been associated with oxi-
dative stress (Maechler and Wollheim 2001; Rosen et al.
2001; Du et al. 2003; Evans et al. 2003; Wiernsperger
2003; Marchetti et al. 2004; Machado and Cortez-Pinto
2005). In addition, metformin has been demonstrated to
be hepatoprotective in models of NAFLD, a condition
also known to be associated with oxidative stress (Lin
et al. 2000; Poon et al. 2003; Bergheim et al. 2006; Mata-
forme et al. 2011; Barbero-Becerra et al. 2012; Cicero
et al. 2012). Although an important part of the beneficial
effects of metformin has been attributed to its (partial)
reversal of insulin-resistance, there are also reports
describing beneficial effects of metformin in nondiabetic
disorders and experimental models, in particular suggest-
ing a protective effect of metformin against oxidative
stress (Poon et al. 2003; Bergheim et al. 2006; El-Mir
et al. 2008; Eriksson et al. 2012; Kita et al. 2012; Bhatt
et al. 2013; Quinn et al. 2013).
In this study, we document that metformin protects pri-
mary rat hepatocytes against oxidative stress-induced apop-
tosis, determined by caspase-9, -6 and -3 activation, the
caspases most intimately involved in menadione-induced










Condition % necrotic cells
Control 2.0 % ± 2.0 %
Menadione (50 µmol/L) 3.4 % ± 2.8 %
Menadione + metformin (0.1 mmol/L) 5.6 % ± 3.0 %
Menadione + metfromin (0.5 mmol/L) 6.4 % ± 3.5 %
Metformin (0.5 mmol/L) 6.8 % ± 2.9 %
Hydrogen peroxide (5 mmol/L) > 75 %
Figure 3. Metformin does not induce necrotic cell death in primary hepatocytes. Cells were incubated with menadione (Men, 50 lmol/L, 9 h)
and without (Con, untreated cells) in the presence and absence of metformin (Met, 0.1 mmol/L and 0.5 mmol/L, added 10 min before
menadione exposure). Sytox Green nucleic staining: necrotic cells represent less than 2% from total cells in all conditions tested. Hepatocytes
exposed to 5 mmol/L hydrogen peroxide was used as positive control for necrosis. Upper panel phase contrast and fluorescence micrographs,
lower panel fluorescence micrographs only. Magnification 40x. Percentages of necrotic cells represent means  SEM. Percentages were calculated
by counting total number of cells and necrotic cells (fluorescent nuclei) in 3 randomly chosen fields in 3 independent experiments.
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apoptosis of rat hepatocytes, and PARP cleavage in a con-
centration-dependent manner. Our results are in accor-
dance with recent studies, in which metformin prevents
high glucose-induced endothelial and neuronal cell death,
at least in part by inhibiting the mitochondrial permeability
transition and/or inhibition of ER stress, resulting in
inhibition of pro-apoptotic JNK activation (Detaille et al.
2005; El-Mir et al. 2008; Eriksson et al. 2012; Jung et al.


























Con Men Ins Men+ Men+ Met+ Men+Met Met
Met Ins Ins Ins
1.0      1.2      2.0       1.4    2.8     3.3      4.0      2.8Relative densitycompared to GAPDH
(A)
(B)
Figure 4. (A) Rosglitazone is not protective against menadione-induced apoptosis in hepatocytes. Cells were incubated with menadione (Men,
50 lmol/L, 9 h) and without (Con, untreated cells) in the presence and absence of the insulin sensitizing compound rosiglitazone (Rosig, 0.5–
10 mmol/L). *P < 0.05 compared to control. #P < 0.05 compared to menadione-treated cells. (B) Insulin-induced phosphorylation of IRS-1 is
slightly but significantly increased by metformin but not modulated by menadione. Densitometric values of bands are expressed relative to
GAPDH with the value of GAPDH in the control condition set as 1. Hepatocytes were exposed to 50 nmol/L insulin in the presence and absence
of 0.5 mmol/L metformin or 50 lmol/L menadione or their combination. Menadione and metformin were added 3 h prior to addition of insulin
and cells were harvested for Western blot analysis 5 min after insulin exposure. IRS-1, insulin receptor substrate-1. GAPDH, glyceraldehyde 3-
phosphate dehydrogenase.
Men 










Figure 5. Metformin prevents oxidative stress-induced JNK
phosphorylation in primary hepatocytes. Cells were exposed to
menadione (Men, 50 lmol/L, 1 h) or not (control, untreated cells) in
the presence and absence of metformin (Met, 0.5 mmol/L, added
10 min before menadione treatment). Western blots were performed







































Figure 6. Metformin increases menadione-induced HO-1
upregulation in a concentration-dependent manner. Quantitative real-
time PCR: cells were incubated with different concentrations of
metformin (Met, 0.1 mmol/L and 0.5 mmol/L, 9 h), added 10 min
before the addition of menadione (Men, 50 lmol/L, 9 h). Statistical
analysis: *P < 0.05 compared to control. #P < 0.05 compared to
menadione-treated cells; n = 3. HO-1, heme oxygenase-1.
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activation of caspases and apoptosis in pancreatic islets
from type 2 diabetic patients (Marchetti et al. 2004). Fur-
thermore, in a recent study, we demonstrated that metfor-
min protects hepatocytes against bile acid-induced
apoptosis, but not against TNFa-induced hepatocyte apop-
tosis (Woudenberg-Vrenken et al. 2013).
Moreover, metformin inhibits caspase-9 activation, sug-
gesting that metformin prevents disruption of mitochon-
dria and subsequent apoptosis (Detaille et al. 2005;
El-Mir et al. 2008; Bhatt et al. 2013). In endothelial cells,
it has been shown that metformin blocks the mitochon-
drial permeability transition and cytochrome c release
induced by high glucose-derived oxidative stress in endo-
thelial cells (Detaille et al. 2005).
In a previous study, we demonstrated that apoptotic
cell death can be switched to necrotic cell death under
certain conditions (Conde de la Rosa et al. 2006). In the
present report, we provide evidence that metformin
indeed protects hepatocytes exposed to oxidative stress
and does not switch apoptotic into necrotic cell death. It
should be realized that apoptosis and necrosis are not
mutually exclusive, but share identical intracellular signal-
ing pathways. Hence, the term necroapoptosis has been
adopted to describe the fact that necrosis and apoptosis
are two sides of the same coin (Nieminen 2003; Nikoleto-
poulou et al. 2013; Stevens et al. 2013). Indeed, Hong
et al. (2009) reported that oxidant stress generated by
O2
• elicits mainly necrotic cell death in an in vivo model
of liver injury. The explanation for this difference between
in vivo and in vitro models has not been elucidated yet,
but may be related to the difference between a culture
model and an in vivo model in which the complex micro-
enviroment, composed of additional cell types, hepatic
sinusoids, hypoxia, etc. may also play a role (Hong et al.
2009). In contrast, the insulin-sensitizing drug rosiglitaz-
one did not show any protective effect against oxidative
stress-induced apoptosis, but rather appeared to aggravate
the effect of oxidative stress. Although metformin slightly
but signiﬁcantly increased insulin-induced phosphorylation
of IRS-1, insulin itself and glitazones do not protect
against oxidative stress-induced cell death. We previously
reported that metformin did induce the phosphorylation of
its down-stream target AMPK, demonstrating that metfor-
min is performing as expected in our hepatocyte culture
system (Woudenberg-Vrenken et al. 2013). These results
indicate that the mechanisms of action metformin and ros-
iglitazone are different and that the protective effect of
metformin is independent of insulin signaling. This is sup-
ported by the fact that all our experiments were performed
in the absence of insulin (unless otherwise indicated).
Previously, we reported that oxidative stress-induced
apoptosis is dependent on JNK pro-apoptotic activity,
since inhibition of JNK activity, using the inhibitor
SP600125, prevents menadione-induced caspase activation
and apoptosis in primary hepatocytes (Conde de la Rosa
et al. 2006, 2008). Concerning the involvement of JNK in
the protective effect of metformin against oxidative
stress-induced apoptosis, we demonstrate that metformin
reduces JNK-phosphorylation and its pro-apoptotic
activity. Therefore, our results indicate that the protective
effect of metformin against oxidative stress-induced
apoptosis is at least in part via inhibition of JNK
activation.
JNK has been described to be a crucial mediator in
insulin resistance and a critical element in the pathogene-
sis of fatty liver disease and type 2 diabetes (Hirosumi
et al. 2002; Wellen and Hotamisligil 2005). JNK activity
has been reported to be highly elevated in diabetes, due
to the presence of inflammation (TNF-a), free fatty acids,
and oxidative stress, all features associated with diabetes
and obesity. JNK can directly phosphorylate IRS-1 induc-
ing defects in insulin signaling and consequently insulin
resistance (Aguirre et al. 2000). Thus, it has been reported
that JNK-deficient obese mice are protected against insu-
lin resistance and defective insulin receptor signaling (Hi-
rosumi et al. 2002). In addition, dominant-negative JNK
isoform in the livers of obese animal results in increased
insulin sensitivity and glucose homeostasis. Furthermore,
exogenous expression of JNK in adult liver results in
insulin resistance in mice (Nakatani et al. 2004). Metfor-
min-induced inhibition of JNK phosphorylation could be
related to its well-known properties as an insulin sensitiz-
ing agent.
However, in our study, experiments were performed in
the absence of insulin. Therefore, it is unlikely that the
protective effect of metformin is related to early events in
insulin signal transduction. Nevertheless, it cannot be







































Figure 7. Metformin induces bcl-xl expression in a concentration-
dependent manner. Quantitative real-time PCR: cells were incubated
with metformin (Met, 0.1 mmol/L and 0.5 mmol/L, 9 h), added
10 min before menadione treatment (Men, 50 lmol/L, 9 h).
*P < 0.05 compared to control. #P < 0.05 compared to menadione-
treated cells; n = 3.
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steps of insulin signal transduction, for example, inhibi-
tion of JNK activation.
The mechanisms by which JNK exert its pro-apoptotic
properties are not completely understood. In many stud-
ies, an effect of JNK has been described at the level of the
mitochondria triggering the mitochondrial death pathway,
including phosphorylation and activation of pro-apopto-
tic bcl-2 family members (Czaja et al. 2003; Tournier
et al. 2000; Okuno et al. 2004; Lei et al. 2002; Chauhan
et al. 2003). Our results correlate with a previous study
in vivo, in which basal protein expression of JNK was
reduced after metformin treatment in Wistar rats
(Cleasby et al. 2004).
HO-1 has been shown to be protective in many studies
(Amersi et al. 1999; Otterbein et al. 1999; Rensing et al.
1999; Kyokane et al. 2001; Chiu et al. 2002; Sass et al.
2003; Dorman et al. 2004; Ryter et al. 2006). Previously,
we demonstrated that overexpression of HO-1, using the
adenovirus Ad5HO-1, leads to protection against oxida-
tive stress (menadione)-induced apoptosis in primary
hepatocytes (Conde de la Rosa et al. 2008). In this report,
we document that metformin further increases menadi-
one-induced HO-1 expression. Metformin alone does not
induce HO-1 expression in primary hepatocytes. Experi-
ments using transition metallo-porphyrins as HO-1 inhib-
itors to confirm the protective effect of HO-1 failed in
our hands, due to strong toxic effects of these com-
pounds. A potential mechanism for metformin-induced
HO-1 expression may be related to hydrogen sulfide
(H2S). It has been shown that hydrogen sulfide induces
HO-1 expression (D’Araio et al. 2014). Interestingly, met-
formin has been reported to increase hydrogen sulfide
levels (Wilinski et al. 2013) and we have preliminary data
that hydrogen sulfide-generating enzymes are present in
hepatocytes. All in all, these results suggest that the
increase of HO-1 expression by metformin contributes to
the protection against oxidative stress-induced apoptosis.
This is the first time that a study shows the involve-
ment of HO-1 induction and JNK inhibition in the
protective effect of metformin against oxidative stress-
induced apoptosis. In our studies, we demonstrated the
protective effect of HO-1 against oxidative stress-induced
apoptotic cell death. However, HO-1 also protects against
necrotic cell death in an in vivo model of acetaminophen
overload (Chiu et al. 2002; Dorman et al. 2004). Since
hepatocyte death in liver disorders most likely has both a
necrotic and apoptotic component, HO-1 induction, and
hence metformin, could be beneficial in liver disorders
accompanied by extensive apoptotic and/or necrotic hepa-
tocyte death. Increased HO-1 expression has also been
shown to correlate with increased expression of anti-
apoptotic bcl-2 family members like bcl-xl (Goodman
et al. 2007; Banerjee et al. 2012). Indeed, we demonstrate
in this study that bcl-xl expression correlates with HO-1
expression and reaches the highest level in response to
the combination metformin and oxidative stress. The
concentrations of metformin used in this study are high
in comparison to the plasma levels achieved during thera-
peutic use of metformin, although they are in line with
metformin concentrations used in many published in
vitro studies. However, our study is important as a ‘proof
of concept’ and could lead to clinical application, e.g.,
using metformin analogs or other agents that induce HO-
1 and/or blc-xl expression. Furthermore, metformin in
high concentrations could be added to preservation/perfu-
sion solutions of donor organs to protect transplanted
organs from oxidative stress-mediated reperfusion injury.
In conclusion, in this study, we demonstrate the pro-
tective role of metformin against oxidative stress-induced
apoptosis in primary hepatocytes. In addition, we report
a completely novel mechanism by which metformin may
protect against apoptosis, involving the induction of HO-
1 and bcl-xl expression and the reduction of JNK activa-
tion. Due to the central role of JNK in pathogenesis of
oxidative stress-mediated diseases, including diabetes and
most chronic liver diseases, modulation of JNK activity
represents a promising and attractive target for the treat-
ment of these disorders.
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